Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study.

Fiche publication

Date publication

mai 2024

Journal

Journal of neurology, neurosurgery, and psychiatry

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme

Tous les auteurs :
Querol L, De Sèze J, Dysgaard T, Levine T, Rao TH, Rivner M, Hartung HP, Kiessling P, Shimizu S, Marmol D, Bozorg A, Colson AO, Massow U, Eftimov F,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38729747

Résumé

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a peripheral nerve disorder characterised by weakness and sensory loss. We assessed the neonatal Fc receptor inhibitor rozanolixizumab for CIDP management.